NCT04615949Phase 2, phase 3Terminated

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Study sponsor: Cardiol Therapeutics Inc. · CRDL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-11-30Actual
Enrollment · participants90Actual
Source updated2026-04-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: All-cause Mortality. After: Measure: Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview